BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, including late stage immuno-oncology agents. The Company’s mission is to develop therapies that provide transformational change to the treatment of cancer through its unique approach to both the science and business of oncology therapeutics. BeyondSpring was established in 2013 and is headquartered in New York City.
Lead asset, Plinabulin, is a new chemical entity (NCE) and a derivative of a natural compound, with a novel immune mechanism of action activating GEF-H1. The drug has shown the potential to provide therapeutic benefit in a variety of cancers, and is currently in pivotal study in its two lead indications of preventing chemotherapy-induced neutropenia and in non-small cell lung cancer (NSCLC). In addition, Plinabulin has shown anti-tumor activity in multiple non-clinical studies in a variety of cancer models, for indications of severe unmet need, including brain tumors and KRAS mutant tumors. BeyondSpring is also expanding its portfolio by internally developing additional drug candidates that it believes may share such game-changing attributes.